Synopsys Inc.

SNPS

Nasdaq; business equipment; SIC 7372, Services-Prepackaged Software; CIK 0000883241

D

fourth fifth of 497 graded peers in business equipment

rank 384 of 497; percentile 77.2; sampling error 2.2 points; lower is stronger

A B C D E

D, the sloth



Scoreboard


Profitability	D	percentile 63.9
Solvency	C	percentile 55.8
Growth and financing	C	percentile 56.7
Reliability	0.94 AUC	filers with over $2.67B assets; 95% interval 0.88 to 0.97; 61 events, 2020 to 2025
Peer failure rate	0.52% a year	Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	over $2.67B assets	total assets $48.2B
Standard universe	inside	revenue above $1M and assets above $10M
Warnings	none triggered	
Inputs computable	12 of 14	
Graded from	filings received through Dec 22, 2025	302 days before the rescan; latest periodic filing 10-Q received Aug 26, 2026
Last close	$454.41	2026-10-19; market equity $87.1B; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Dec 22, 2025

Synopsys, Inc. (Synopsys, we, our or us) is the leader in engineering solutions from silicon to systems, enabling customers to rapidly innovate AI-powered products. We deliver trusted and comprehensive solutions spanning silicon design, silicon intellectual property (IP), simulation and analysis (S&A) as well as design services. We partner closely with our customers across a wide range of industries to maximize their R&D capability and productivity, powering innovation today that ignites the ingenuity of tomorrow.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight


Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 63.9						
Gross profitability	11.3%	28.6%		81.5	557	2025-10-31
Return on invested capital	not computable	11.0%				
a prior annual debt, equity, and cash observation is required						
Accruals ratio	(0.6%)	(7.4%)		84.3	620	2025-10-31

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Gross margin stability, five years	1.3 pts	2.3 pts	25.8	427	2025-10-31
Solvency, sleeve percentile 55.8					
Twelve-month failure probability	0.04%	0.05%	30.7	102	2026-07-31
Altman Z double-prime	2.63	2.16	40.1	564	2025-10-31
Net debt to EBITDA	6.73x	1.11x	92.5	147	2025-10-31
Interest coverage	not computable	3.77x			
latest aligned inputs end 2023-10-31; latest annual assets end 2025-10-31					
Current ratio	1.62x	2.01x	59.9	664	2025-10-31
Growth and financing, sleeve percentile 56.7					
Revenue growth, three-year compound	15.2%	6.4%	25.9	537	2025-10-31
Free cash flow growth, three-year compound	(5.6%)	17.7%	82.3	266	2025-10-31
Reinvestment rate	(230.1%)	13.5%	84.8	225	2025-10-31
Asset growth, three years	72.4%	5.0%	3.9	562	2025-10-31
Net share issuance, one year	23.8%	0.5%	86.6	410	2025-12-15

Among 497 peers

business equipment; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
379	AmpliTech Group, Inc. (AMPGZ)	76.1	D	fortress balance sheet
380	C3.ai, Inc. (AI)	76.4	D	
381	Airgain Inc. (AIRG)	76.6	D	
382	Marchex Inc. (MCHX)	76.8	D	
383	Harvard Bioscience Inc. (HBIO)	77.0	D	
384	Synopsys Inc. (SNPS)	77.2	D	
385	Duos Technologies Group, Inc. (DUOT)	77.4	D	dilution, late filer, fortress balance sheet
386	Spectrum Brands Holdings, Inc. (SPB)	77.6	D	
387	GoodRx Holdings, Inc. (GDRX)	77.8	D/E	
388	Asure Software Inc. (ASUR)	78.0	D/E	
389	Thermo Fisher Scientific Inc. (TMO)	78.2	D/E	

What the price implies

at the 2026-10-19 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(10.9%)	2.2%	40
Distance from 52-week high	(15.0%)	(31.8%)	76
EBIT to enterprise value	1.0%	1.5%	44
Free cash flow yield	1.5%	2.8%	36
Book value to price	0.36	0.25	60
Sales to price	0.08	0.33	13
Composite equity issuance, five years	22.5%	4.2%	74
Relative strength against the sector, log excess return	(0.40)	(0.26)	40

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score 3 of 9, period end 2025-10-31	
Return on assets above zero	pass
Operating cash flow above zero	pass
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	$3.6B
Operating cash flow, four quarters	$2.9B
Months of runway	not finite
Days since last periodic filing	55 (10-Q received Aug 26, 2026)
Median daily dollar volume, 63 sessions	$739.7M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	$5.4B	2025-10-31	2025-12-22	10-K	25-000028
2	assets	us-gaap:Assets	$48.2B	2025-10-31	2025-12-22	10-K	25-000028
3	operating income	us-gaap:OperatingIncomeLoss	$914.9M	2025-10-31	2025-12-22	10-K	25-000028
4	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	$1.4B	2025-10-31	2025-12-22	10-K	25-000028
5	income tax	us-gaap:IncomeTaxExpenseBenefit	$56.0M	2025-10-31	2025-12-22	10-K	25-000028
6	total debt	us-gaap:LongTermDebt	$13.5B	2025-10-31	2025-12-22	10-K	25-000028
7	book equity	us-gaap:StockholdersEquity	$28.3B	2025-10-31	2025-12-22	10-K	25-000028
8	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$2.9B	2025-10-31	2025-12-22	10-K	25-000028
9	net income	us-gaap:NetIncomeLoss	$1.3B	2025-10-31	2025-12-22	10-K	25-000028
10	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$1.5B	2025-10-31	2025-12-22	10-K	25-000028
11	assets	us-gaap:Assets	$13.1B	2024-10-31	2025-12-22	10-K	25-000028
12	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$7.1B	2025-10-31	2025-12-22	10-K	25-000028
13	gross profit	us-gaap:GrossProfit	$4.9B	2024-10-31	2025-12-22	10-K	25-000028
14	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$6.1B	2024-10-31	2025-12-22	10-K	25-000028
15	gross profit	us-gaap:GrossProfit	$4.3B	2023-10-31	2025-12-22	10-K	25-000028
16	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$5.3B	2023-10-31	2025-12-22	10-K	25-000028
17	gross profit	us-gaap:GrossProfit	$3.7B	2022-10-31	2024-12-19	10-K	24-000024
18	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$4.6B	2022-10-31	2024-12-19	10-K	24-000024
19	gross profit	us-gaap:GrossProfit	$3.3B	2021-10-31	2023-12-12	10-K	23-000019
20	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$4.2B	2021-10-31	2023-12-12	10-K	23-000019
21	current assets	us-gaap:AssetsCurrent	$6.0B	2025-10-31	2025-12-22	10-K	25-000028
22	current liabilities	us-gaap:LiabilitiesCurrent	$3.7B	2025-10-31	2025-12-22	10-K	25-000028
23	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	$10.3B	2025-10-31	2025-12-22	10-K	25-000028
24	liabilities	us-gaap:Liabilities	$19.9B	2025-10-31	2025-12-22	10-K	25-000028
25	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	$660.4M	2025-10-31	2025-12-22	10-K	25-000028
26	operating income	us-gaap:OperatingIncomeLoss	$1.3B	2023-10-31	2025-12-22	10-K	25-000028
27	interest expense	us-gaap:InterestExpense	$1.2M	2023-10-31	2023-12-12	10-K	23-000019
28	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$169.5M	2025-10-31	2025-12-22	10-K	25-000028
29	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$1.4B	2024-10-31	2025-12-22	10-K	25-000028
30	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$139.5M	2024-10-31	2025-12-22	10-K	25-000028
31	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$1.7B	2023-10-31	2025-12-22	10-K	25-000028

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

32	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$189.6M	2023-10-31	2025-12-22	10-K	25-000028
33	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$1.7B	2022-10-31	2024-12-19	10-K	24-000024
34	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$136.6M	2022-10-31	2024-12-19	10-K	24-000024
35	current assets	us-gaap:AssetsCurrent	$6.5B	2024-10-31	2025-12-22	10-K	25-000028
36	current liabilities	us-gaap:LiabilitiesCurrent	$2.7B	2024-10-31	2025-12-22	10-K	25-000028
37	assets	us-gaap:Assets	$10.3B	2023-10-31	2024-12-19	10-K	24-000024
38	assets	us-gaap:Assets	$9.4B	2022-10-31	2023-12-12	10-K	23-000019
39	shares outstanding	dei:EntityCommonStockSharesOutstanding	191,318,206	2025-12-15	2025-12-22	10-K	25-000028
40	shares outstanding	dei:EntityCommonStockSharesOutstanding	154,578,449	2024-12-16	2024-12-19	10-K	24-000024

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.